Navigation Links
Stereotaxis Reports 26% Third Quarter 2009 Revenue Growth

ST. LOUIS, Nov. 5 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) today reported strong revenue growth, a significant increase in the gross margin, lower operating expenses and a significant reduction in the net loss for both the quarter and the nine month period ended September 30, 2009. Revenue for the recent third quarter totaled $13.3 million, an increase of 26% over $10.6 million for the 2008 third quarter. During the quarter, the Company recognized revenue on six Niobe® Magnetic Navigation Systems and seven Odyssey(TM) systems totaling $8.7 million. Disposables, services and accessories revenue reached a record $4.6 million, a 45% increase from the third quarter of 2008. Gross profit margin was 68% compared with 65% in the third quarter of 2008. Operating expenses declined 18% from the third quarter last year to $13.2 million.

For the first nine months of 2009, revenue grew 31% to $37.1 million compared with $28.2 million in the first nine months of 2008. Recurring revenue grew 56% from $8.6 million to $13.4 million and gross margin increased 37% to $24.7 million, or 67% of sales. Operating expenses decreased 19%, resulting in a 48% reduction in the operating loss to $18.0 million for the first nine months of 2009 compared with a $34.6 million operating loss in the same period in 2008.

Michael P. Kaminski, President and Chief Executive Officer, said, "The third quarter financial results reflect a solid improvement in our Company's march to breakeven. We remain focused on driving revenue growth and strong margins while controlling operating expenses, resulting in a significant reduction in our cash burn to $3.5 million. We are particularly excited about the introduction of the Odyssey platform for non-magnetic labs as seen by the first multiple system order for non-magnetic labs in September. There is tremendous interest in the Odyssey and Cinema platform driven by increased market awareness and recognition of the system value. By consolidating many diverse sources of diagnostic and other information into a single manageable format, Odyssey offers improved procedure efficiency, enhanced archiving and a unique opportunity to network labs and sites together for educational and consulting purposes, creating a platform for improved quality of care. We have experienced significant market interest in this platform and anticipate it becoming a third leg to our revenue growth in 2010."

"We are pleased with the third quarter recurring revenue of $4.6 million and the 45% growth over prior year but recognize that the challenge of driving clinical adoption is a process focused on moving the market to a new standard of care. We will continue to shift more resources into this important initiative to maximize our adoption at existing sites and to support the growth of the installed base."

"During the quarter, we generated $6.3 million of new capital orders, up from $5.0 million in the second quarter. We are encouraged by the increase in new orders, which along with our backlog, positions us well for continued growth. Lastly, with the infusion of $28 million in net proceeds from our recent capital raise and our incremental improvement in cash burn, we believe the Company is positioned well to execute its growth plan and strategy in 2010 and beyond," Mr. Kaminski concluded.

Third Quarter 2009 Financial Performance

Gross margin for the quarter was $9.0 million, or 68% of revenue, compared with $6.9 million, or 65% of revenue, in the third quarter of 2008. Third quarter operating expenses decreased 18% to $13.2 million from $16.1 million in the third quarter of 2008.

The operating loss in the third quarter decreased significantly to $(4.2) million compared with $(9.2) million in the prior year. The Company reported a net loss for the third quarter of 2009 of $(5.8) million, or $(0.14) per share. This compares with a net loss for the third quarter of 2008 of $(10.1) million, or $(0.28) per share. The weighted average shares for the recent third quarter totaled 42.0 million compared with 36.6 million in the third quarter of last year. The increase was due in large part to the issuance of 4.4 million shares as part of two concurrent private placements of stock completed in December 2008.

Cash used in operations was $3.5 million for the third quarter of 2009 compared with $5.5 million in the third quarter of 2008. Cash and equivalents at September 30, 2009 totaled $12.0 million, compared with $30.4 million at December 31, 2008. Total debt was $30.8 million, including $16.2 million drawn against the Company's $25 million line of credit. As previously disclosed, in October 2009 the Company received a commitment to expand its line of credit from $25 million to $30 million and to extend the maturity date from March 31, 2010 to March 31, 2011.

On October 15, 2009, the Company completed a public stock offering, issuing a total of 7,475,000 shares of common stock, including the exercise of the underwriter's over-allotment. The transaction was priced at $4.00 per share, representing gross proceeds of $29.9 million. Net of transaction costs, Stereotaxis received approximately $28 million in cash. This transaction will be reflected in the fourth quarter and year-end financial statements.

2009 Financial Guidance

The Company reiterates its outlook for 2009 as follows:

  • Total revenue for 2009 is expected to exceed 2008 revenue.
  • Gross margins above 65%.
  • Operating expenses are now expected to be below $60 million for the full year 2009.

Conference Call Information

The Company has scheduled a conference call for 8:30 a.m. Eastern Time today to discuss its financial results for the third quarter. To access the conference call, please dial (877) 941-8631. International participants can call (480) 629-9822. An audio replay of the call will be available for seven days following the call at (800) 406-7325 for U.S. callers or (303) 590-3030 for those calling outside the U.S. The password required to access the replay is 4171622#. The call will also be available on the Internet live and for 90 days thereafter at the following URL:

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Stereotaxis system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

                                    STEREOTAXIS, INC.
                                 STATEMENTS OF OPERATIONS

                           Three Months Ended          Nine Months Ended
                              September 30,              September 30,
                           ------------------          -----------------
                           2009          2008          2009         2008
                           ----          ----          ----         ----
       System         $8,671,302    $7,365,480   $23,694,613   $19,641,188
        service and
        accessories    4,619,391     3,186,169    13,373,484     8,597,503
                       ---------     ---------    ----------     ---------
    Total revenue     13,290,693    10,551,649    37,068,097    28,238,691

    Cost of revenue
       System          3,474,492     3,098,477     9,250,005     8,822,745
        service and
        accessories      811,089       543,071     3,162,142     1,427,501
                         -------       -------     ---------     ---------
    Total cost of
     revenue           4,285,581     3,641,548    12,412,147    10,250,246

    Gross margin       9,005,112     6,910,101    24,655,950    17,988,445

    Operating expenses:
     Research and
      development      3,302,008     4,380,466    10,247,877    13,861,339
     Sales and
      marketing        6,290,814     7,012,264    21,424,796    23,297,003
     General and
      administration   3,654,207     4,719,779    11,006,981    15,458,115
                       ---------     ---------    ----------    ----------
    Total operating
     expenses         13,247,029    16,112,509    42,679,654    52,616,457
                      ----------    ----------    ----------    ----------
    Operating loss    (4,241,917)   (9,202,408)  (18,023,704)  (34,628,012)
    income/(expense)    (489,139)            -        66,507             -
    Interest income        2,721        33,711        34,069       165,665
     expense          (1,085,408)     (904,428)   (2,860,479)   (1,931,606)
                     -----------      --------   -----------   -----------
    Net loss         $(5,813,743) $(10,073,125) $(20,783,607) $(36,393,953)
                     ===========  ============  ============  ============

     Net loss per
      common share:
        Basic and
         diluted          $(0.14)       $(0.28)       $(0.50)       $(1.00)
                          ======        ======        ======        ======

    Weighted average
     shares used in
     computing net
     loss per common
      Basic and
       diluted        41,985,315    36,612,877    41,648,104    36,541,593
                      ==========    ==========    ==========    ==========
                                      STEREOTAXIS, INC.
                                       BALANCE SHEETS

                                               September 30,  December 31,
                                                     2009          2008
                                                     ----          ----
    Current Assets:
     Cash and cash equivalents                  $12,012,659   $30,355,657
     Accounts receivable, net of allowance
      of $265,208 and $328,307 in 2009 and
      2008, respectively                         11,547,727     9,739,008
     Current portion of long-term receivables       340,333       197,351
     Inventories                                  6,979,759     8,086,956
     Prepaid expenses and other current
      assets                                      3,149,122     2,966,510
                                                  ---------     ---------
    Total current assets                         34,029,600    51,345,482
    Property and equipment, net                   5,106,215     6,420,600
    Intangible assets                             1,177,778     1,277,778
    Long-term Receivables                           142,723       298,123
    Other assets                                     27,162        98,382
                                                     ------        ------
    Total assets                                $40,483,478   $59,440,365
                                                ===========   ===========

    Liabilities and stockholders' equity
    Current liabilities:
       Current maturities of long-term debt      $8,734,824    $3,901,491
       Accounts payable                           4,084,037     4,561,928
       Accrued liabilities                        7,962,313     9,873,818
       Deferred contract revenue                  6,895,840     9,676,339
       Warrants                                   4,988,084             -
                                                  ---------           ---
    Total current liabilities                    32,665,098    28,013,576

    Long term debt, less current maturities      22,057,304    25,271,547
    Long term deferred contract revenue           1,014,592     1,225,656
    Other liabilities                                12,963       158,905

    Stockholders' equity:
       Preferred stock, par value $0.001;
        10,000,000 shares authorized at 2009
        and 2008; none outstanding at 2009
        and 2008                                          -             -
       Common stock, par value $0.001;
        100,000,000 shares authorized at 2009
        and 2008; 42,783,451 and 42,049,792
        issued at 2009 and 2008, respectively        42,783        42,050
       Additional paid-in capital               301,638,671   300,892,957
       Treasury stock, 40,151 shares at 2009
        and 2008                                   (205,999)     (205,999)
       Accumulated deficit                     (316,741,934) (295,958,327)
                                               ------------  ------------
    Total stockholders' equity                  (15,266,479)    4,770,681
                                                -----------     ---------
    Total liabilities and stockholders'
     equity                                     $40,483,478   $59,440,365
                                                ===========   ===========

SOURCE Stereotaxis, Inc.

SOURCE Stereotaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
2. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
3. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
4. Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook
5. Stereotaxis Receives $20 Million in Additional Loan Commitments
6. Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference
7. Stereotaxis Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
8. Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe
9. Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases
10. Stereotaxis to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. Stereotaxis Reports Record First Quarter Orders
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... An inventor, from Hopkinsville, Ky., thought there ... home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. provides ... so, it could help to prevent potential overdose situations. As a result, it ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
Breaking Medicine Technology: